These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8178907)

  • 21. Oral contraception with a triphasic combination of gestodene and ethinyl estradiol: results of a multicenter clinical study.
    Skouby SO
    Int J Fertil; 1987; 32 Suppl():45-8. PubMed ID: 2906346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
    Bilotta P; Favilli S
    Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group.
    Bruni V; Croxatto H; De La Cruz J; Dhont M; Durlot F; Fernandes MT; Andrade RP; Weisberg E; Rhoa M
    Gynecol Endocrinol; 2000 Apr; 14(2):90-8. PubMed ID: 10836195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
    Ferreira AC; Montes MB; Franceschini SA; Toloi MR
    Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The characteristics of triphasic estrogen-progesterone contraceptives and their theoretical indications].
    Senèze J
    Rev Fr Gynecol Obstet; 1990 May; 85(5):301-5. PubMed ID: 2374864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of long-term gestodene-containing oral contraceptive administration on hemostasis.
    Abbate R; Pinto S; Rostagno C; Bruni V; Rosati D; Mariani G
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):424-9. PubMed ID: 2372036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
    Benagiano G
    Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Third generation progestagens].
    Belaisch J; Eliakim V
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):287-93. PubMed ID: 12318226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women.
    Petersen KR; Sidelmann J; Skouby SO; Jespersen J
    Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):32-8. PubMed ID: 8420344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A clinical overview of a new triphasic contraceptive containing gestodene.
    Christie T
    Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
    Kuhl H; März W; Jung-Hoffmann C; Heidt F; Gross W
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):363-9. PubMed ID: 2142576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical comparison of monophasic oral contraceptive preparations of gestodene/ethinyl estradiol and desogestrel/ethinyl estradiol. Latin American Oral Contraceptive Study Group.
    Contraception; 1994 Sep; 50(3):201-14. PubMed ID: 7805371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combined estrogen-progestagen contraception and glucid and water-sodium metabolism].
    Belaisch J; Hommais-loufrani B
    Contracept Fertil Sex (Paris); 1988 Feb; 16(2):3-7. PubMed ID: 12342001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological and endocrine profiles of gestodene.
    Spona J; Huber J
    Int J Fertil; 1987; 32 Suppl():6-14. PubMed ID: 2906347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The clinical and lipid metabolic effects of a gestoden- and ethynyl estradiol-based monophasic contraceptive].
    Pérez Peña E; Lamas Flores R
    Ginecol Obstet Mex; 1993 Nov; 61():329-34. PubMed ID: 8288137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR; Gaspard UJ
    Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins.
    Speroff L; DeCherney A
    Obstet Gynecol; 1993 Jun; 81(6):1034-47. PubMed ID: 8497347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.